JP2017535555A5 - - Google Patents

Download PDF

Info

Publication number
JP2017535555A5
JP2017535555A5 JP2017526523A JP2017526523A JP2017535555A5 JP 2017535555 A5 JP2017535555 A5 JP 2017535555A5 JP 2017526523 A JP2017526523 A JP 2017526523A JP 2017526523 A JP2017526523 A JP 2017526523A JP 2017535555 A5 JP2017535555 A5 JP 2017535555A5
Authority
JP
Japan
Prior art keywords
treprostinil
dcm
dmf
dioxane
coupling reagent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017526523A
Other languages
English (en)
Other versions
JP2017535555A (ja
JP6866043B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061427 external-priority patent/WO2016081658A1/en
Publication of JP2017535555A publication Critical patent/JP2017535555A/ja
Publication of JP2017535555A5 publication Critical patent/JP2017535555A5/ja
Application granted granted Critical
Publication of JP6866043B2 publication Critical patent/JP6866043B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (19)

  1. 次式:
    Figure 2017535555

    を有するトレプロスチニルプロドラッグの製造方法であって、
    カップリング試薬の存在下に、トレプロスチニルを式R−NHの化合物(式中、Rは直鎖もしくは分岐C〜C18アルキル、直鎖C〜C18アルケニル、または分岐C〜C18アルケニル、アリール、アリール−C〜C18アルキル、アミノ酸またはペプチドである)と混合することと、
    この混合物を式(B)の化合物が生成するのに十分な期間インキュベートすることと
    を含む、方法。
  2. 前記カップリング試薬が1−[ビス(ジメチルアミノ)メチレン]−1H−1,2,3−トリアゾロ[4,5−b]ピリジニウム3−オキシドヘキサフルオロリン酸(HATU)である、請求項1に記載の方法。
  3. 前記カップリング試薬がベンゾトリアゾール−1−イルオキシトリピロリジノホスホニウムヘキサフルオロリン酸塩(PyBOP)である、請求項1に記載の方法。
  4. 前記カップリング試薬が炭酸N,N’−ジイソスクシンイミジル(DSC)である、請求項1に記載の方法。
  5. 前記カップリング試薬がN,N’−ジシクロヘキシルカルボジイミド(DCC)、N,N’−ジイソプロピルカルボジイミド(DIC)またはN−(3−ジメチルアミノプロピル)−N’−エチルカルボジイミド塩酸塩(EDC)である、請求項1に記載の方法。
  6. トレプロスチニルおよび前記カップリング試薬をある期間混合した後、式 −NH の化合物がトレプロスチニルおよび前記カップリング試薬に添加される、請求項1〜5のいずれか一項に記載の方法。
  7. 前記期間が約30分間〜約96時間、約30分間〜約72時間、約30分間〜約48時間、約30分間〜約24時間または約30分間〜約150分間である、請求項6に記載の方法。
  8. トレプロスチニルが溶媒に溶解されている、請求項1〜のいずれか一項に記載の方法。
  9. 前記溶媒がジオキサンを含む、請求項に記載の方法。
  10. 前記溶媒がアセトニトリル(MeCN)、N,N’−ジメチルホルムアミド(DMF)、ジクロロメタン(DCM)またはこれらの組合せを含む、請求項に記載の方法。
  11. 前記溶媒が、ジオキサン(2mL/100μmol トレプロスチニル)、ジオキサン(1mL/100μmol トレプロスチニル)、DMF、DCM、MeCN、ジオキサン:MeCN(1:1)、DMF/DCM、10%DMF/DCMまたは20%DMF/DCMを含む、請求項に記載の方法。
  12. 次式:
    Figure 2017535555

    を有するトレプロスチニルプロドラッグの製造方法であって、
    酸触媒の存在下に、トレプロスチニルを式R−OH(式中、Rは、直鎖もしくは分岐C〜C18アルキル、直鎖C〜C18アルケニル、または分岐C〜C18アルケニル、アリール、アリール−C〜C18アルキル、アミノ酸またはペプチドである)のアルコールと混合することと、
    この混合物を式(A)の化合物が生成するのに十分な期間インキュベートすることと
    を含む、方法。
  13. トレプロスチニルが、前記酸触媒と混合される前に溶媒に溶解される、請求項12に記載の方法。
  14. 前記溶媒がジオキサンを含む、請求項13に記載の方法。
  15. 前記溶媒が、アセトニトリル(MeCN)、N,N’−ジメチルホルムアミド(DMF)、ジクロロメタン(DCM)またはこれらの組合せを含む、請求項13に記載の方法。
  16. 前記溶媒が、ジオキサン(2mL/100μmol トレプロスチニル)、ジオキサン(1mL/100μmol トレプロスチニル)、DMF、DCM、MeCN、ジオキサン:MeCN(1:1)、DMF/DCM、10%DMF/DCMまたは20%DMF/DCMを含む、請求項13に記載の方法。
  17. 前記酸触媒が固体である、請求項12〜16のいずれか一項に記載の方法。
  18. 前記固体が固体樹脂である、請求項17に記載の方法。
  19. 前記酸触媒が、硫酸、スルホン酸、フッ化水素酸、リン酸、トルエンスルホン酸、ポリスチレンスルホン酸塩、ヘテロポリ酸、ゼオライト、金属酸化物、グラフェンオキシジェンまたはこれらの組合せを含む、請求項12〜18のいずれか一項に記載の方法。
JP2017526523A 2014-11-18 2015-11-18 トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法 Active JP6866043B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081515P 2014-11-18 2014-11-18
US62/081,515 2014-11-18
PCT/US2015/061427 WO2016081658A1 (en) 2014-11-18 2015-11-18 Methods of manufacturing treprostinil and treprostinil derivative prodrugs

Publications (3)

Publication Number Publication Date
JP2017535555A JP2017535555A (ja) 2017-11-30
JP2017535555A5 true JP2017535555A5 (ja) 2018-12-27
JP6866043B2 JP6866043B2 (ja) 2021-04-28

Family

ID=56014536

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526523A Active JP6866043B2 (ja) 2014-11-18 2015-11-18 トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法

Country Status (8)

Country Link
US (4) US10343979B2 (ja)
EP (2) EP3221291B1 (ja)
JP (1) JP6866043B2 (ja)
AU (1) AU2015349969B2 (ja)
CA (1) CA2967385C (ja)
ES (1) ES2873873T3 (ja)
HK (1) HK1244783A1 (ja)
WO (1) WO2016081658A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
EA031604B1 (ru) 2013-10-25 2019-01-31 Инсмед Инкорпорейтед Трепростинильные соединения, композиции и способы их использования
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
WO2017223400A1 (en) * 2016-06-24 2017-12-28 Insmed Incorporated Prostacyclin compounds and compositions for treating sarcoidosis
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
CN114616225A (zh) 2019-08-23 2022-06-10 联合治疗公司 曲前列环素前药
US10781160B1 (en) * 2019-10-04 2020-09-22 Chirogate International Inc. Hexadecyl Treprostinil crystals and methods for preparation thereof
AU2021255621A1 (en) 2020-04-17 2022-10-20 United Therapeutics Corporation Treprostinil for use in the treatment of intersitial lung disease
JP2023529828A (ja) 2020-06-09 2023-07-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
IL303668A (en) 2020-12-14 2023-08-01 United Therapeutics Corp Stable treprostinil prodrugs and their uses for the treatment of diseases
WO2022187352A1 (en) 2021-03-03 2022-09-09 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
US20230263807A1 (en) 2022-02-08 2023-08-24 United Therapeutics Corporation Treprostinil iloprost combination therapy

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2947526A1 (de) 1978-11-29 1980-06-12 Ono Pharmaceutical Co Prostacyclin-analoge
US4668814A (en) 1984-03-08 1987-05-26 The Upjohn Company Interphenylene carbacyclin derivatives
JPS61289034A (ja) 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
US4837342A (en) 1986-02-28 1989-06-06 Sagami Chemical Research Center Prostacyclin analogue, and blood circulation improving agent and anti-ulcer composition containing it as active ingredient
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
GB9011588D0 (en) 1990-05-24 1990-07-11 Wellcome Found Prostaglandin analogues for use in medicine
US6165500A (en) 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
CA2056039A1 (en) 1991-01-22 1992-07-23 Philip L. Fuchs Carbacyclin analogs
US5190972A (en) 1992-01-27 1993-03-02 The University Of Melbourne Method of combatting cyclosporine organ toxicity with prostaglandin analogs
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US6638621B2 (en) 2000-08-16 2003-10-28 Lyotropic Therapeutics, Inc. Coated particles, methods of making and using
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
KR100638684B1 (ko) 1997-11-14 2006-10-27 유나이티드 세러퓨틱스 코오포레이션 말초 혈관 질환의 치료를 위한 9-데옥시-2',9-알파-메타노-3-옥사-4,5,6-트리노르-3,7-(1',3'-인터페닐렌)-13,14-디하이드로-프로스타글란딘 에프1의 용도
AU742250B2 (en) 1997-12-26 2001-12-20 Astellas Pharma Inc. Sustained release medicinal compositions
EP1100464A1 (en) 1998-07-31 2001-05-23 Korea Institute Of Science And Technology Lipid emulsion and solid lipid nanoparticle as a gene or drug carrier
US6265495B1 (en) * 1998-09-22 2001-07-24 Nippon Shokubai Co., Ltd. Method for production of esterified product
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
AU4327300A (en) 1999-03-31 2000-10-16 United Therapeutics Corporation Prostaglandin compounds, compositions and methods of treating peripheral vascular disease and pulmonary hypertension
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
WO2003000236A1 (en) 2001-06-23 2003-01-03 Lyotropic Therapeutics, Inc Particles with improved solubilization capacity
US20030108512A1 (en) 2001-12-10 2003-06-12 Robert Shorr Modified prostaglandin compounds and analogs thereof, compositions containing the same useful for the treatment of cancer
US6803386B2 (en) 2002-01-16 2004-10-12 United Therapeutics Corporation Prostacyclin derivative containing compositions and methods of using the same for the treatment of cancer
US20040156816A1 (en) 2002-08-06 2004-08-12 David Anderson Lipid-drug complexes in reversed liquid and liquid crystalline phases
US20050244503A1 (en) 2003-05-19 2005-11-03 Rabinow Barrett E Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
ATE341312T1 (de) 2003-05-20 2006-10-15 Ethypharm Sa Orale pharmazeutische zusammensetzung mit verzögerter freisetzung
ES2622471T5 (es) * 2003-05-22 2020-07-23 United Therapeutics Corp Compuestos y procedimientos para la administración de análogos de prostaciclina
WO2005058329A1 (en) 2003-12-16 2005-06-30 United Therapeutics Corporation Use of treprostinil to improve kidney functions
US8765813B2 (en) 2003-12-16 2014-07-01 United Therapeutics Corporation Use of treprostinil to treat and prevent ischemic lesions
JP2007532663A (ja) 2004-04-12 2007-11-15 ユナイテッド セラピューティクス インコーポレイテッド ニューロパシー性の糖尿病性足潰瘍を治療するためのトレプロスチニルの使用
GB0416328D0 (en) 2004-07-21 2004-08-25 Univ Cardiff Use of dry powder compositions for pulmonary delivery
US20060147520A1 (en) 2004-07-26 2006-07-06 Curtis Ruegg Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
EP1806148A4 (en) 2004-10-22 2009-12-02 Ono Pharmaceutical Co THERAPEUTIC PREPARATION FOR INHALATION
EP1973523A2 (en) 2005-12-15 2008-10-01 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
WO2008098196A1 (en) 2007-02-09 2008-08-14 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
ES2728785T3 (es) 2007-09-07 2019-10-28 United Therapeutics Corp Soluciones tampón con actividad bactericida selectiva contra las bacterias gramnegativas y métodos para usarlas
KR101898407B1 (ko) 2007-12-17 2018-09-12 유나이티드 세러퓨틱스 코오포레이션 레모둘린®의 활성 성분인 트레프로스티닐의 개선된 제조 방법
WO2009137066A1 (en) 2008-05-08 2009-11-12 United Therapeutics Corporation Treprostinil monohydrate
WO2009152160A1 (en) 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
WO2009158010A1 (en) 2008-06-27 2009-12-30 Concert Pharmaceuticals, Inc. Prostacyclin analogs
WO2010039531A1 (en) 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Therapeutic compounds
WO2010036798A1 (en) 2008-09-25 2010-04-01 Aradigm Corporation Deep lung pulmonary delivery of treprostinil
MX2011008647A (es) 2009-02-20 2011-10-28 Micro Labs Ltd Producto de prostaglandina de almacenamiento estable.
KR101544246B1 (ko) 2009-05-07 2015-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린 유사체의 고체 제제
JP6087147B2 (ja) 2009-06-22 2017-03-01 ジョンソン、マッセイ、パブリック、リミテッド、カンパニーJohnson Matthey Public Limited Company プロスタグランジンの精製方法
US20120270934A1 (en) 2009-07-03 2012-10-25 Concert Pharmaceuticals, Inc. Prostacyclin derivatives
JP5877787B2 (ja) 2009-08-07 2016-03-08 サイファーム ソシエテ ア レスポンサビリテ リミテSciPharmS.a r.l. 嚢胞性線維症の治療のための組成物
US20120232034A1 (en) 2009-08-21 2012-09-13 Henk-Andre Kroon Vesicular formulations
CN101669904B (zh) 2009-09-29 2011-06-22 北京中海康医药科技发展有限公司 一种依前列醇脂质纳米粒及制备方法
DK2525830T3 (en) 2010-01-22 2016-08-15 Ascendis Pharma As DIPEPTID-BASED PRODRUG LINKERS TO ALIFATIC AMINE-CONTAINING MEDICINES
WO2011089215A1 (en) 2010-01-22 2011-07-28 Ascendis Pharma As Dipeptide-based prodrug linkers for aromatic amine-containing drugs
KR20150027846A (ko) 2010-03-15 2015-03-12 유나이티드 세러퓨틱스 코오포레이션 폐고혈압의 치료
ES2658139T3 (es) 2010-06-03 2018-03-08 United Therapeutics Corporation Producción de treprostinil
EP2582235A4 (en) 2010-06-15 2014-04-30 United Therapeutics Corp ORAL TREATMENT OF DIGITAL ISCHEMIC LESIONS
US20120010159A1 (en) 2010-07-09 2012-01-12 United Therapeutics Corporation Combination therapies with cox-2 inhibitors and treprostinil
CA2710726C (en) 2010-07-22 2016-02-23 Alphora Research Inc. Synthesis of treprostinil and intermediates useful therein
WO2012107364A1 (en) 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
JP5780775B2 (ja) 2011-02-18 2015-09-16 株式会社Lttバイオファーマ プロスタグランジンi2誘導体を含有するナノ粒子
EP2681204B1 (en) 2011-03-02 2016-04-27 United Therapeutics Corporation Synthesis of intermediate for treprostinil production
ES2832330T3 (es) 2011-03-14 2021-06-10 Univ Hokkaido Nat Univ Corp Vector para administración pulmonar, agente inductor y usos
EP2741778A1 (en) 2011-08-12 2014-06-18 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
AU2012296951B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S Protein carrier-linked prodrugs
US20140296257A1 (en) 2011-08-12 2014-10-02 Ascendis Pharma A/S High-Loading Water-Soluable Carrier-Linked Prodrugs
CN103874480A (zh) 2011-08-12 2014-06-18 阿森迪斯药物股份有限公司 前列环素的缓释组合物
MX349950B (es) 2011-08-12 2017-08-22 Ascendis Pharma As Profarmacos de treprostinil enlazados a un portador.
EP3643306A3 (en) 2011-08-12 2020-08-26 Ascendis Pharma A/S Carrier-linked prodrugs having reversible carboxylic ester linkages
US8524939B2 (en) 2011-08-24 2013-09-03 Chirogate International Inc. Intermediates for the synthesis of benzindene prostaglandins and preparations thereof
US9387214B2 (en) 2012-01-13 2016-07-12 United Therapeutics Corporation Method of identifying therapies for pulmonary hypertension
DK2674413T3 (en) 2012-06-15 2017-09-18 Scipharm Sàrl Process for the Preparation of Treprostinil and Derivatives Thereof
KR102143961B1 (ko) 2012-08-01 2020-08-12 유나이티드 세러퓨틱스 코오포레이션 프로스타시클린-처리된 내피 전구 세포를 사용한 폐동맥 고혈압의 치료
EP2879682B1 (en) 2012-08-01 2018-03-21 United Therapeutics Corporation Treatment of pulmonary arterial hypertension with mesenchymal stem cells
CA2890219A1 (en) 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
ES2697573T3 (es) 2013-01-09 2019-01-25 United Therapeutics Corp Tratamiento de la vasculopatía con prostaciclina y células madre mesenquimatosas
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (es) * 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
CA3212313A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
EP2970081A4 (en) 2013-03-15 2016-10-12 United Therapeutics Corp SALTS OF TREPROSTINIL
WO2014160638A1 (en) 2013-03-25 2014-10-02 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
WO2014203278A2 (en) 2013-06-19 2014-12-24 Msn Laboratories Private Limited NOVEL PROCESS FOR THE PREPARATION OF (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-HEXAHYDRO-2-HYDROXY-1-[(3S)-3-HYDROXYOCTYL]-1H-BENZ[f]INDEN-5-YL]OXY]ACETIC ACID
US9925184B2 (en) 2013-10-11 2018-03-27 Pulmokine, Inc. Spray-dry formulations
EA031604B1 (ru) * 2013-10-25 2019-01-31 Инсмед Инкорпорейтед Трепростинильные соединения, композиции и способы их использования
WO2015138423A1 (en) 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
US20170095432A1 (en) 2014-06-13 2017-04-06 United Therapeutics Corporation Treprostinil formulations
CA2964804C (en) 2014-10-20 2019-04-02 United Therapeutics Corporation Synthesis of intermediate for producing prostacyclin derivatives
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
WO2016176555A1 (en) 2015-04-29 2016-11-03 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
AU2017261317A1 (en) 2016-05-05 2018-12-13 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
WO2017223400A1 (en) 2016-06-24 2017-12-28 Insmed Incorporated Prostacyclin compounds and compositions for treating sarcoidosis
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
EP3673895A1 (en) 2018-12-28 2020-07-01 Université Libre de Bruxelles Dry powder inhalation formulation and its use for the therapeutic treatment of lungs
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법

Similar Documents

Publication Publication Date Title
JP2017535555A5 (ja)
JP2017511305A5 (ja)
JP2008523069A5 (ja)
JP2017061563A5 (ja)
TWI645901B (zh) 雙環烷基化合物及合成
EA201070874A1 (ru) Производные индол-2-карбоксамидов и азаиндол-2-карбоксамидов, замещённых силанильной группой, их получение и применение в терапии
JP5735659B2 (ja) シタグリプチンの中間体の製造方法
JP2013518962A5 (ja)
JP2012508235A5 (ja)
JP2014015483A5 (ja)
JP2010512316A5 (ja)
JP2015518473A5 (ja)
RU2020105524A (ru) Алкоксилированные сложные эфирамины и их соли
DE602006008962D1 (de) Verfahren zur herstellung von valsartan
RU2011115572A (ru) Группа аминозамещенных бензоилпроизводных, их получение и применение
RU2013119617A (ru) Способ получения 2-амино-n-(2, 2, 2-трифторэтил)ацетамида
JP2012531508A5 (ja)
JP2011524871A5 (ja)
ES2320323T3 (es) Procedimiento para la preparacion de poliamidas ciclicas con proteccion n-1 que contienen atomos de nitrogeno en forma de anillo n, y producto asi obtenido.
JP2018502174A5 (ja)
JP2010529044A5 (ja)
RU2011118583A (ru) 5-о-производные авермектина, способ их получения и антипаразитарные средства на их основе
JP2017513885A5 (ja)
PE20090824A1 (es) Proceso para la preparacion de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterociclicas
JP2015508069A5 (ja)